Andere talen Lexaria Bioscience Corp.

Aandelen

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,35 ^USD	+7,31%		+6,82%	+88,00%

16/04	Lexaria Bioscience Corp. Ontvangt goedkeuring van de ethische toetsingscommissie om te beginnen met een nieuwe GLP-1 studie	CI
09/04	Lexaria Bioscience Corp. Rapporteert resultaten voor het tweede kwartaal en de zes maanden eindigend op 29 februari 2024	CI

Lexaria Obtains Ethics Review Board Approval to Start New GLP-1 Study	16/04
Lexaria Bioscience Corp. Receives Ethics Review Board Approval to Begin New GLP-1 Study	16/04
Lexaria Bioscience : Corporate Highlight Sheet	11/04
Lexaria Bioscience Corp. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	09/04
Lexaria Bioscience Corp. Receives New Patents in the Fields of Epilepsy and Anti-Viral Agents	02/04
Lexaria Awarded New Patents	02/04
Lexaria Bioscience : Amendment of a Material Definitive Agreement - Form 8-K	21/03
Lexaria to Present at The LD Micro Invitational XIV	21/03
Lexaria Bioscience Names Nelson Cabatuan as Finance Chief	14/03
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer	14/03
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer	14/03
Lexaria Bioscience : Corporate Highlight Sheet	08/03
Lexaria Awards Contract For Next GLP-1 Human Pilot Study	07/03
Sector Update: Health Care Stocks Retreating Late Afternoon	05/03
Sector Update: Health Care	05/03
Lexaria Bioscience to Start Diabetes, Weight Loss Animal Study; Shares Rise	05/03
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1	05/03
Lexaria to Begin Diabetes and Weight Loss Animal Study Well-A24-1	05/03
Lexaria Bioscience Corp. Signs Contracts to Begin Animal Study Well-A24-1	04/03
7% Weight Loss in Animals Supports Lexaria's Next 8-week Animal Study	04/03

Geen resultaten voor deze zoekopdracht